Ep. 199 "TB Testing in the Era of IL‑17 and IL‑23 Inhibitors"

In this episode, Dr. Andrew Blauvelt and Dr. G. Scott Drew talk with NPF CSMO Dr. Guy Eakin about when—and whether—TB testing is needed before initiating psoriasis therapies. Listeners can read the NPF/IPC position paper referenced here: https://www.jaad.org/article/S0190-9622(25)03232-3/fulltext Key Takeaways: 1. Data show that the progression from latent tuberculosis infection to active disease during psoriasis treatment with IL-17 or IL-23 is rare. 2. TB testing may still be appropriate for specific patients and in certain clinical conditions. 3. Updated NPF and IPC joint position statement, published in JAAD, aims to drive practice change. This podcast is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $375,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by CDC/HHS, or the U.S. Government.